Hjem
Oddbjørn Straumes bilde

Oddbjørn Straume

Professor
  • E-postOddbjorn.Straume@uib.no
  • Telefon+47 55 09 40 31
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Lærebok
  • Vis forfatter(e) (2016). MEDIKAMENTELL KREFTBEHANDLING - Cytostatikaboken 8. utgave, Kapittel 34 - Malignt melanom. Universitetet i Oslo, Det medisinske fakultet, Institutt for klinisk medisin, Avdeling for farmakologi.
Vitenskapelig artikkel
  • Vis forfatter(e) (2021). Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. International Journal of Cancer. 100-111.
  • Vis forfatter(e) (2021). Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. Scientific Reports. 1-11.
  • Vis forfatter(e) (2020). HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective? . PharmacoEconomics - Open. 529-539.
  • Vis forfatter(e) (2020). AXL is a driver of stemness in normal mammary gland and breast cancer. iScience. 1-40.
  • Vis forfatter(e) (2019). ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Scientific Reports. 1-15.
  • Vis forfatter(e) (2019). Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. The journal of pathology. Clinical research. 53-62.
  • Vis forfatter(e) (2019). Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. Cancer Treatment and Research Communications. 1-5.
  • Vis forfatter(e) (2019). Distant metastasis dynamics following subsequent surgeries after primary breast cancer removal . Breast Cancer Research. 1-10.
  • Vis forfatter(e) (2019). Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology. 1154-1161.
  • Vis forfatter(e) (2019). Are 90% of deaths from cancer caused by metastases? Cancer Medicine. 5574-5576.
  • Vis forfatter(e) (2018). Tumour cell expression of interleukin 6 receptor a is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. The journal of pathology. Clinical research. 114-123.
  • Vis forfatter(e) (2017). Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. BMC Urology. 1-11.
  • Vis forfatter(e) (2017). Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years. JAMA Internal Medicine. 1774-1780.
  • Vis forfatter(e) (2016). The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases. Breast Cancer Research and Treatment. 169-178.
  • Vis forfatter(e) (2016). Expression of Heat Shock Protein 27 in melanoma metastases is associated with overall response to bevacizumab monotherapy: Analyses of predictive markers in a clinical phase II study. PLOS ONE.
  • Vis forfatter(e) (2015). Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Research Notes. 1-5.
  • Vis forfatter(e) (2014). Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors. Molecular Cancer Research. 754-764.
  • Vis forfatter(e) (2014). Nestin expression is associated with aggressive cutaneous melanoma of the nodular type. Modern Pathology. 396-401.
  • Vis forfatter(e) (2014). Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases. Breast Cancer Research and Treatment. 627-636.
  • Vis forfatter(e) (2013). Vascular proliferation is associated with survival in pancreatic ductal adenocarcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1037-1046.
  • Vis forfatter(e) (2012). Vascular proliferation is a prognostic factor in breast cancer. Breast Cancer Research and Treatment. 501-510.
  • Vis forfatter(e) (2012). Tumor necrosis is a prognostic factor in thick cutaneous melanoma. American Journal of Surgical Pathology. 1477-1482.
  • Vis forfatter(e) (2012). Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 8699-8704.
  • Vis forfatter(e) (2012). Prognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma. Journal of Investigative Dermatology. 1247-1252.
  • Vis forfatter(e) (2012). Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLOS ONE. 8 sider.
  • Vis forfatter(e) (2011). Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. British Journal of Cancer. 9-12.
  • Vis forfatter(e) (2010). Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 15 sider.
  • Vis forfatter(e) (2009). Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clinical and Experimental Metastasis. 51-60.
  • Vis forfatter(e) (2009). Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clinical Cancer Research. 3484-3494.
  • Vis forfatter(e) (2008). Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer. 362-372.
  • Vis forfatter(e) (2008). Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clinical and Experimental Metastasis. 51-60.
  • Vis forfatter(e) (2008). Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma research. 29-35.
  • Vis forfatter(e) (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology. 268-273.
  • Vis forfatter(e) (2006). A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype. Journal of the National Cancer Institute. 316-325.
  • Vis forfatter(e) (2005). Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. British Journal of Cancer. 933-938.
  • Vis forfatter(e) (2005). Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clinical Cancer Research. 8606-8614.
  • Vis forfatter(e) (2005). BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. Journal of Investigative Dermatology. 312-317.
  • Vis forfatter(e) (2001). Expression of vascular endothelial growth factor, its receptors (FLT-1. KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. American Journal of Pathology. 223-35.
  • Vis forfatter(e) (2001). A single nucleotide polymorphism in the 3' untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. International Journal of Cancer. 388-93.
  • Vis forfatter(e) (2000). Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clinical Cancer Research. 1845-53.
  • Vis forfatter(e) (2000). Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans. Anticancer Research. 4857-62.
  • Vis forfatter(e) (1999). Loss of nuclear expression of p16 protein correlates with increased tumor cell proliferation and poor patient outcome in patients with vertical growth phase melanoma. (Abstract no. P-487). Virchows Archiv. 314.
  • Vis forfatter(e) (1999). Angiogenesis is prognostically important in vertical growth phase melanomas. International Journal of Oncology. 595-599.
Faglig foredrag
  • Vis forfatter(e) (2013). Angiogenesis as a treatment target in metastatic melanoma.
Vitenskapelig foredrag
  • Vis forfatter(e) (2016). Recurrence of breast cancer in relation to delayed reconstruction.
  • Vis forfatter(e) (2016). Hva betyr sekundær rekonstruksjon for senere tilbakefall?
  • Vis forfatter(e) (2013). Nye behandlingsformer for inoperabelt metastatisk malignt melanom.
  • Vis forfatter(e) (2013). Angiogenesis as a treatment target in melanoma.
  • Vis forfatter(e) (2003). Mutation analysis of the RAS-RAF pathway in pancreatic adenocarcinomas and malignant melanomas.
Short communication
  • Vis forfatter(e) (2004). Lymphatic vessel density and prognosis in cutaneous melanoma. British Journal of Cancer. 1224-1225.
Brev til redaktøren
  • Vis forfatter(e) (2006). Bevacizumab therapy for POEMS syndrome. Blood. 4973-4974.
Doktorgradsavhandling
  • Vis forfatter(e) (2016). Investigation of predictive markers in patients with metastatic melanoma treated with bevacizumab.
  • Vis forfatter(e) (2002). Biological and prognostic markers in cutaneous malignant melanoma. -.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2017). The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. 26 sider.
Sammendrag/abstract
  • Vis forfatter(e) (2018). Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma. Annals of Oncology. viii452-viii452.
Poster
  • Vis forfatter(e) (2019). Perioperative factors and complications after delayed reconstruction in breast cancer patients in relation to oncologic outcome.
  • Vis forfatter(e) (2018). Surgeries reveal details of metastasis development.
  • Vis forfatter(e) (2017). Predictive value of IL6Rα in patients with metastatic clear cell renal cell carcinoma treated with sunitinib.
  • Vis forfatter(e) (2015). C-reactive protein as a predictive marker of response to sunitinib treatment in metastatic clear cell renal cell carcinoma.
  • Vis forfatter(e) (2009). Suppression of heat shock Protein 27 induces long-term dormancy in human breast cancer.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2019). The link between wound healing and escape from tumor dormancy. Surgial oncology. 50-56.
  • Vis forfatter(e) (2013). Tumor vasculature: the Achilles' heel of cancer? Expert opinion on therapeutic targets. 7-20.
  • Vis forfatter(e) (2013). Malignt melanom – diagnostikk, behandling og oppfølging i Norge. Tidsskrift for Den norske legeforening. 2154-2159.
  • Vis forfatter(e) (2008). Tumor-vascular interactions and tumor dormancy. APMIS - Journal of Pathologiy, Microbiology and Immunology. 569-585.
Faglig kapittel
  • Vis forfatter(e) (2016). Signalhemmere. 282-328. I:
    • Vis forfatter(e) (2016). Medikamentell kreftbehandling - Cytostatikaboken 8. utgave 2016. Avdeling for farmakologi, Universitetet i Oslo.

Se fullstendig oversikt over publikasjoner i CRIStin.